BioHarvest's Pivot: A Signed Fragrance Contract Rewrites the D2C Story
Guidance cut, EBITDA re-routed, and a 20-ton rare-fragrance offtake that doesn't pay until 2027 — but the CDMO lens is now the whole pitch.
BHST · Earnings Call · 2026-08-11
A first transferable contract
For a company that spent years validating its Botanical Synthesis platform through a direct-to-consumer VINIA business, the headline out of the Q2 2026 print is a genuine unlock: its first-ever CDMO manufacturing and supply agreement. The customer is UAE-based; the product is a global luxury rare fragrance raw material; the commitment is 20 tons across 2027–2028, worth an estimated “$20 million to $30 million in revenue for BioHarvest in the 2027, 2028 time frame” — Zaki Rakib, Chairman and Chief Executive Officer · 2026-08-11, with BioHarvest retaining a 20% ownership in the venture plus royalties that are still to be negotiated. Rakib framed it as a structural validation:
This is the real first ever contract of this magnitude, $20 million to $30 million magnitude is just the beginning. It's just the tip of the iceberg of what Botanical Synthesis can do covering so many industries…
The acceleration is the point. On the May 2026 call he said he had “the opportunity to smell success and see success. I smelled the fragrance that we are developing” — Zaki Rakib, Chief Executive Officer · 2026-05-14 — and expected it to reach market “in the second half of next year” — Zaki Rakib, Chief Executive Officer · 2026-05-14 (2027). Now, limited production starts in the first half of 2027 with revenue recognized from product sales in H1 2027, and larger bioreactors arriving mid-year for the 2028 ramp. "It is significantly ahead of the schedule we had previously outlined." The manufacturing agreement also converts a lab triumph into recurring revenue — management reasserted the standing $180M five-year projection and, pointedly, its exclusivity: “We're the exclusive manufacturer. I mean I can't see anyone else being able to deliver such a product.” — Zaki Rakib, Chairman and Chief Executive Officer · 2026-08-11
The great reallocation
The fragrance deal lands at the same moment the company is deliberately throttling its D2C engine. Full-year 2026 revenue guidance is cut from $42–48M to $37–40M, with the VINIA D2C segment reduced from $38–42M to $33–35M and flipped to an EBITDA loss of $1.5–2.5M versus a prior expected gain of $0.5–2M. Active customers held steady at roughly 95,000; the cut is framed as a choice, not decay — “This reflects a deliberate reallocation of spend, not a deterioration in the underlying business” — Zaki Rakib, Chairman and Chief Executive Officer · 2026-08-11 — and the mechanism is explicit: “Our view is that the right response is not to spend more into that environment, but to change what we put in front of the consumer.” — Zaki Rakib, Chairman and Chief Executive Officer · 2026-08-11 Meta media costs rose double digits, so rather than pay up for acquisition, BioHarvest redirected spend to manufacturing capacity and the CDMO. June brought the first price increase since May 2021 (up to 20% for new subscribers from their second order), and single-dose Daily Chews launch in September to lift conversion rates among younger cohorts.
The counter-intuitive financial tell sits inside the CDMO guidance: revenue was actually tightened down — from $4–6M to $4–5M — while the full-year CDMO EBITDA loss was cut from $4–5M to $1.5–2.5M. That is a deliberate "value over number" shift: “Instead of chasing a significant number of opportunities… it's value more than number” — Zaki Rakib, Chairman and Chief Executive Officer · 2026-08-11 — focusing resources on high-margin projects, especially the fragrance, which needs manufacturing attention. Management now targets consolidated EBITDA breakeven in 2027 with a slightly wider 2026 consolidated loss ($3–5M vs prior $3–4M), and is managing cash with the “intent to avoid raising equity-based funding” — Zaki Rakib, Chairman and Chief Executive Officer · 2026-08-11 against the $16.2M balance sheet.
Saffron, sweeteners, and the model's shape
The pivot to a CDMO-first model is visible across the pipeline. Saffron passed Stage 1 and triggered a $1.125M Stage 2 (scaling biomass in bioreactors), with BioHarvest retaining a 25% ownership stake plus future manufacturing royalties. The Tate & Lyle collaboration — about to be supercharged by the Ingredion combination — was broadened from a single compound to several sweetener molecules, and Rakib floated a licensing model where the partner builds its own facility and BioHarvest collects technology-transfer fees and royalties rather than consuming CapEx. The Israel Innovation Authority approved a ~$1.4M non-dilutive grant to integrate data science and machine learning into plant-cell-culture workflows.
What to watch: the near-term P&L now carries two different stories. On one hand, this micro-cap ($84M market cap) is still reporting a modest 3.8% revenue quarter ($8.8M), a 58% gross margin, and a $1.6M adjusted EBITDA loss. On the other, the entire narrative hinges on 2027 — the fragrance offtake, saffron royalties, a new 20–40 ton facility, and EBITDA breakeven — while previously planned consumer launches (olive, pomegranate, other molecules) are being shelved and offered to CDMO customers instead. Investors are being asked to pay for a CDMO that today generates almost no revenue, and to accept a VINIA business that is stalling by design. The reallocation of spend is the wager; the next two quarters will test whether it reads as discipline or stall.